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Abstract: Background: Temporomandibular joint osteoarthritis (TMJ-OA) is a degenerative dis-
ease that involves changes in subchondral bone and progressive degradation of cartilage. Currently, 
rebamipide, a gastroprotective drug, is administered to protect gastric mucosa and accelerate ulcer 
healing.  
Objectives: Recent studies have shown that rebamipide also attenuates cartilage degeneration by 
suppressing oxidative damage and inducing homeostasis of the extracellular matrix of articular 
chondrocytes. Regarding the latter, reduced expression of cathepsin K, NFATc1, c-Src, and integrin 
3, and increased expression of nuclear factor-kappa B, have been found to be mediated by the tran-
scription factor, receptor activator of nuclear factor kappa-B ligand (RANKL).  
Methods: Treatment with rebamipide was also found to activate, mitogen-activated protein kinases 
such as p38, ERK, and JNK to reduce osteoclast differentiation. Taken together, these results 
strongly indicate that rebamipide mediates inhibitory effects on cartilage degradation and osteoclas-
togenesis in TMJ-OA. 
Results and Conclusion: Here, we highlight recent evidence regarding the potential for rebamipide 
to affect osteoclast differentiation and TMJ-OA pathogenesis. We also discuss the potential role of 
rebamipide to serve as a new strategy for the treatment of TMJ-OA. 
Keywords: Rebamipide, osteoclast differentiation, ROS, chondrocyte, TMJ-OA, mitogen-activated. 
1. INTRODUCTION 
 Temporomandibular joint osteoarthritis (TMJ-OA) is a 
degenerative disease that reflects both non-inflammatory and 
inflammatory changes. TMJ-OA may involve all TMJ tis-
sues and leads to anatomical changes [1, 2]. It is character-
ized by chronic inflammation in synovial tissue, progressive 
cartilage destruction and deterioration, and subchondral bone 
remodeling. The etiology is associated with multiple risk 
factors, complex, and sometimes unknown. However, the 
exact pathogenesis of TMJ-OA remains unclear and contro-
versial. Osteoarthritis (OA) often affects the TMJ of patients 
with temporomandibular disorders (TMDs). Thus, TMJ-OA 
is an important subtype in the classification of TMDs [1, 3-
5]. 
 Patients with TMJ-OA often have pain and TMJ dysfunc-
tion with decreased quality of life [6]. The clinical signs and 
symptoms of TMJ-OA include a restriction in joint function  
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and severe pain due to the presence of synovitis [3]. The pain 
usually associated with limitation of joint opening, stiffness, 
and may be relieved with rest and nonsteroid anti-
inflammatory drug (NSAID) treatment [6]. Drug reposition-
ing or reprofiling has a significant advantage over traditional 
drug development because a repositioned drug has already 
completed toxicity and safety tests and exhibited reduced 
toxicology. Investigations of new pleiotropic effects of drugs 
are very valuable and can enhance the success of pharmaceu-
tical companies [7].  
 Rebamipide is an amino acid analog of 2 (1H)-quinolone 
and is widely used as a gastroprotective drug to treat gastric 
ulcers and gastritis. Rebamipide has also exhibited antibacte-
rial effects, mucin secretagogue activity, and anti-
inflammatory actions [7-11]. In endothelial inflammation, 
rebamipide suppresses interleukin (IL)-8 production through 
inhibition of IB phosphorylation and nuclear factor-kappa 
B (NF-B) p65 [12]. Rebamipide also inhibits T cells activa-
tion, suppresses Th1 cytokines (IL-2 and interferon-), serum 
autoantibodies, IgM, and IgG1 production, and decreases 
NF-B activity in autoimmune lesions of salivary glands 
[13]. 
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 Moreover, recent studies have demonstrated the treat-
ment effects of rebamipide for new indications such as TMJ-
OA and its potency to inhibit the formation of human osteo-
clasts (OCs) by inhibition of RANKL-mediated osteoclasto-
genesis, disruption of actin ring formation, and reduction of 
DC-specific transmembrane protein (DC-STAMP) [7, 14]. In 
OA cartilage, rebamipide attenuates matrix metalloprotein-
ase (MMP)-13, IL-1, hypoxia inducible factor (HIF)-2, 
inducible nitric oxide synthase (iNOS), and nitrotyrosine 
[15]. Most of the studies suggest that rebamipide might be a 
potential therapeutic strategy for OA.  
 Bone is a tissue that is continuously remodeled via two 
distinct processes, bone resorption and bone formation [16]. 
To maintain skeletal homeostasis, these events are tightly 
regulated and strongly linked [17]. OCs are critical for both 
processes and they include bone resorbing cells which repre-
sent differentiated cells that derive from hematopoietic cells 
of monocyte-macrophage lineages. Conversely, osteoblasts 
(OBs), which derive from mesenchymal origins, are respon-
sible for bone forming cells. When the differentia-
tion/activity of OCs and OBs is altered, bone diseases can 
develop. Moreover, accumulating evidence supports the ex-
istence of a relationship between bone and the immune sys-
tem, particularly in relation to pathological conditions in 
which activation of bone adsorption and bone resorption 
occurs [18]. 
 RANK is expressed by OC progenitor cells and its acti-
vation by RANKL results in the downstream stimulation of 
factors associated with tumor necrotic factor (TNF) recep-
tor, as well as several signaling cascades including mito-
gen-activated protein kinase (MAPK), NF-B, activating 
protein 1 (AP-1), and the transcription factor, nuclear factor 
of activated T-cells c1 (NFATc1). Cross-talk between these 
signaling proteins results in the formation of OCs that are 
multinucleated and exhibit bone resorbing activity [19, 20]. 
Terminal differentiation of OCs is characterized by expres-
sion of c-Src, integrin 3, cathepsin K, NFATc1, and other 
markers of OC differentiation [20, 21] (Fig. 1). In this re-
view, the effect of rebamipide on the differentiation and 
function of OCs both in vitro and in vivo is described in an 
effort to develop a novel strategy to treat OC-associated 
bone diseases. 
2. TMJ-OA 
 OA is the most common degenerative joint disorder that 
causes disability in the adult population [22]. OA patients 
suffer from pain during increased function and load bearing 
joint. The joints become tender, with decreased range of mo-
tion, and loss of articular cartilage indicated by crepitus. Ra-
diography may show joint space narrowing, formation of 
osteophytes [23, 24], subchondral bone cysts, condylar head 
flattening, and increased subchondral cortical thickness [25, 
26].  
 TMJ is frequently affected by OA [27, 28]. The preva-
lence of TMJ-OA has been observed to be 25% in 20-49 
year age group and 70% in 73-75 year age group by clinical 
and MRI examination [27, 29]. The evidence of TMJ-OA is 
clinically indicated by female preponderance, with a fe-
male-to-male ratio of more than 2:1 [30, 31]. TMJ-OA has 
various etiologies and multifactorial factors including in-
flammatory, immunologic insults, biomechanical, bio-
chemical, excessive mechanical stress, and extracartilagi-
nous factor. The extracartilaginous factors include reduc-
tion of synovial fluid, changes in synovial membrane, 
changes in vascular system, and subchondral bone mi-
crofractures [32, 33]. 
 The pathogenesis of TMJ-OA can be caused by various 
etiologic factors that each interact with the other and each of 
etiologic factor may not cause the same pathogenesis. Liter-
ally, the subchondral bone has an etiological role in the 
pathogenesis of TMJ-OA. Failure in internal remodeling 
system of mandibular condylar subchondral bone may result 
chondrocyte injury then leads to increase collagen degrada-
tion, with release of proteases and decrease of protease in-
hibitor thereby resulting in extracellular matrix (ECM) 
breakdown [33]. 
 Various key mediators have been suggested to be respon-
sible for degradation of articular cartilage in vivo and in vitro 
including MMP-13 and members of the closely related fam-
ily of a disintegrin and metalloprotease with thrombospondin 
motifs 5 (ADAMTS5) [34-39]. During the process of TMJ-
OA, articular chondrocytes release IL-1, TNF-, runt-related 
transcription factor 2 (RUNX2), alkaline phosphatase, and 
type 10 collagen. Concurrently, abnormal cartilage calcifica-
Fig. (1). Rebamipide affected osteoclastogenesis. Early nonspecific differentiation of OCs, survival cytokine M-CSF, and macrophage 
proliferation are dependent on PU.1. Subsequently, RANKL-induced activation of RANK commits OCs to differentiation via c-Fos and 
NFATc1. Polarization, which requires c-Src and v3 integrin, is the first step in establishing the resorptive capacity of mature OCs. 
Osteoclasts then mobilize the mineralized component of bone, with cathepsin K mediating degradation of the organic matrix of bone. In the 
present study, rebamipide treatment decreased RANKL-induced NFATc1 signaling and levels of c-Src and v3 integrin. As a result, 
expression of cathepsin K was affected. 
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tion occurs and exhibits decrease levels of proteoglycan [40-
45]. 
3. REBAMIPIDE AND THE DIFFERENTIATION OF 
OCs 
 Multinucleated cells that attach to the bone matrix via an 
actin rich structure are referred to as OCs. The actin rings 
that are formed by OCs degrade bone matrix following the 
secretion of protons and proteases into a space that forms 
between OCs and a bone surface through a specialized struc-
ture known as a ruffled border membrane [46]. OC differen-
tiation is regulated by colony stimulating factor 1 receptor 
(Csf1r), also known as M-CSF receptor or c-Fms, and tumor 
necrosis factor receptor superfamily member 11a 
(Tnfrsf11a), also known as receptor activator of NF-B 
(RANK) [47]. While M-CSF receptor signaling supports the 
survival and proliferation of OC precursor cells during os-
teoclastogenesis, the differentiation process of OCs is acti-
vated by RANK signaling. RANK signaling activates NF-B 
and Fos, both of which are transcription factors that are es-
sential for OC differentiation [21]. Ig-like receptors transmit 
signals to activate phospholipase C (PLC) via their adap-
tors, DAP12 and FcR, with each containing an immunore-
ceptor tyrosine-based activation motif (ITAM) [48]. PLC 
then induces calcium oscillation, which leads to the activa-
tion of calcineurin, a Ca
2+
/calmodulin-dependent phospha-
tase. RANK and Ig-like receptor signals are finally inte-
grated by the master transcription factor of osteoclastogene-
sis, NFATc1, which induces the expression of molecules that 
allow OCs to perform bone resorbing activities. These mole-
cules include MMP-9, cathepsin K, the chloride channel, 
CLC-7, and H
+
-ATPase subunits [49]. 
 Rebamipide treatment of bone marrow macrophages 
(BMMs) and human monocytes inhibits RANKL-induced 
OC formation from precursor cells in a dose-dependent 
manner without cytotoxicity. Thus, rebamipide affects the 
generation of OCs from macrophage that are stimulated with 
RANKL and also the differentiation of OCs [7, 14].  
4. REBAMIPIDE SUPPRESSES GENE EXPRESSION 
IN OCs 
 Previous studies have reported that rebamipide inhibits 
IL-8 expression that is induced by TNF- by suppressing 
NF-B signaling in human umbilical vein endothelial cells 
(HUVECs). Rebamipide also inhibits the adhesion of endo-
thelial cells to endothelial cells that are stimulated by hy-
poxia/reoxygenation through an NF-B-dependent pathway 
[12, 50]. For RANKL-induced OC differentiation, the NF-
B pathway must be activated [49]. Activation of the IB 
kinase complex is a well-characterized aspect of the classical 
NF-B signaling pathway, and it leads to phosphorylation of 
IB which targets it for ubiquitin-dependent degradation 
[51]. We have shown that rebamipide inhibits the degrada-
tion of IB in the cytoplasm to reduce transactivation of 
NF-B [14]. 
 It has been reported that MAPKs (e.g. p38, JNK, and 
ERK) are activated by RANKL stimulation and they play a 
role in osteoclastogenesis [19]. In the early stages of OC 
generation, p38 is particularly important based on its ability 
to regulate microphthalmia-associated transcription factor 
[52]. Meanwhile, dominant-negative JNK has been shown to 
prevent osteoclastogenesis induced by RANKL [53]. ERK is 
able to induce c-Fos for osteoclastogenesis [54], while inhi-
bition of ERK reduces OC formation [55]. In the present 
study, activation of these MAPKs was investigated following 
rebamipide treatment, and it was observed that rebamipide 
inhibits the phosphorylation of each. Thus, the anti-
osteoclastogenic effect of rebamipide in RANKL-stimulated 
BMMs may be mediated via the phosphorylation of various 
MAPKs [20] (Fig. 2). 
5. REBAMIPIDE DISRUPTS THE CYTOSKELETAL 
ORGANIZATION OF OCs TO INHIBIT BONE-
RESORBING ACTIVITY 
 Degradation of the inorganic and organic matrices of 
bone is a crucial function of OCs. The accumulation of 
molecules that are able to degrade bone on the resorption 
Fig. (2). Rebamipide-induced chondroprotective effects in TMJ-OA. TMJ-OA that was treated with rebamipide exhibited suppressed 
chondrocyte apoptosis, expression of MMP-13, and oxidative damage in a dose-dependent manner. A reduction in condylar subchondral 
bone volume due to blocked OC activity via RANKL-induced osteoclastogenesis was also readily observed.  
Potential Role of Rebamipide in Osteoclast Differentiation Current Rheumatology Reviews, 2018, Vol. 14, No. 1    65 
surface of bone requires direct interactions between OCs and 
mineralized substrates. OCs create a microenvironment that 
is isolated from the extracellular space by restructuring the 
actin component of their cytoskeleton. Specifically, actin 
rings are formed that provide a “gasket-like” sealing of this 
microenvironment [56]. 
 In the present study, assays to detect pit formation in-
duced by RANKL show that rebamipide inhibits the ability 
of OCs to perform bone-resorbing activities. In addition, 
rebamipide treatment leads to the degradation of actin rings 
of mature OCs in a dose-dependent manner. However, fol-
lowing the exposure of bone marrow stromal cells to re-
bamipide, -glycerophosphate, and osteoblastogenic me-
dium, the mineralization and differentiation of the OCs were 
unaffected. Thus, rebamipide appears to mediate an anti-
resorption effect, while indirectly affecting the formation of 
bone [14]. 
6. MURINE MODEL OF TMDs 
 As a synovial joint, the TMJ is essential for sliding and 
hinge movements of jaws [57]. The TMJ consists of the con-
dyle, articular eminence, and glenoid fossa, and it provides 
articulation between the mandible and the cranium. These 
joints are surrounded by a capsule consisting of a synovial 
lining and fibrous material and they provide anatomic con-
trol of both occlusion and mandibular movement. An articu-
lar disk separates the joint space between the condyle and the 
glenoid fossa into lower and upper articular cavities and 
these are bounded by the condyle and the articular eminence 
and articular fossa, respectively [58, 59].  
 TMDs include a heterogenous cluster of diseases [60-62]. 
In particular, rheumatoid arthritis (RA) and OA of the TMJ 
represent severe and debilitating disorders whereby the TMJ 
disk can undergo displacement, thickening, folding, length-
ening, and disk perforation [63-65]. However, the factors 
responsible for the development and progression of TMD, 
especially OA in the TMJ, remain to be determined [57]. 
 As compared to articular cartilage in the knee, mandibu-
lar condyle cartilage is considered secondary (e.g. from the 
chondroskeleton) and it derives from the cranial neural crest 
during embryogenesis. Compared to other synovial joints 
and the articular cartilage of other joints, the condyle of the 
mandible has less type I collagen and does not express type 
II collagen in the superficial layer of mandibular condylar 
cartilage. In addition, the articular surfaces of the mandible 
are composed of fibrous tissue rather than hyaline cartilage. 
For studies of TMDs, specific devices and methods have 
been applied to establish mouse and rat models of these dis-
eases. In addition, various genetic animal models of OA 
have been established [66]. 
 The TMJ-OA model established in the present study ex-
hibited irregularities in chondrocyte alignment in the condy-
lar cartilage layers, OA-like degenerated lesions, marked 
depletion of proteoglycans, and subchondral bone loss due to 
OC hyperactivity. Previously, it was demonstrated that 
forced mouth opening in mice led to a decrease in subchon-
dral bone volume [67], while steady and repetitive jaw open-
ing was an effective method for inducing OA-like changes in 
rabbits. Moreover, the latter were consistent with the presen-
tation of TMJ-OA in patients [68]. Biomechanical stimula-
tion from abnormal occlusion [69, 70], local application of 
chemicals [3], surgical manipulation of the joint [71], and 
genetic modifications [72, 73] have also been shown to in-
duce early TMJ-OA. 
7. REBAMIPIDE AND AUTOIMMUNITY 
 In a recent study, adjunct rebamipide therapy was found 
to effectively prevent peptic ulcers in patients that were pre-
scribed a COX-2-selective inhibitor for arthritis [74]. Oral 
administration of rebamipide has also been found to reduce 
histological and clinical scores in animal models of RA, par-
ticularly in SKG mice and animals with arthritis induced by 
collagen [75, 76]. RA leads to inflammation of the synovial 
membrane and involves the production of IL-17, IL-1, IL-6, 
and TNF-.  Expression of RANKL is also enhanced in 
synovial cells, thereby inducing OC differentiation. Consid-
ering these results, as well as the observation that CD4+ T 
cell activation is suppressed by rebamipide, it is possible that 
rebamipide may also be useful for the healing of bone de-
struction that is impaired by OCs [7, 13, 77]. 
 Decreased apoptosis of epithelial cells in the salivary 
glands has been observed in rebamipide-treated mice. Re-
bamipide treatment has also been found to suppress the acti-
vation of Th1 cytokines (IL-2, interferon-) and CD4+ T-
cells, thereby adversely affecting NF-B activity and inhibit-
ing the expression of IRF-4B, a transcription factor associ-
ated with B-cell activation and differentiation. Thus, re-
bamipide may represent a novel therapeutic approach for 
Sjorgen syndrome [13].  
8. THE ROS-SCAVENGING PROPERTY OF RE-
BAMIPIDE AND TMJ-OA 
 Active oxygen species that are generated by polymor-
phonuclear leukocytes represent a potential source of dam-
age to cells. Meanwhile, reactive oxygen metabolites that are 
generated during the metabolism of arachidonic acid, smooth 
muscle cells, and platelet macrophages may contribute to the 
damage of gastric mucosa. A pharmacological effect of re-
bamipide includes its ability to scavenge hydroxyl radicals 
and attenuate the cytotoxicity of reactive oxygen metabo-
lites. In regard to gastric mucosal damage, rebamipide has 
the potential to scavenge hydroxyl radicals and also suppress 
the production of active oxidants by modulating the activa-
tion of neutrophils [78-80]. 
 A recent report described the inhibitory effects of re-
bamipide on cartilage degeneration and pain production in an 
experimentally induced model of OA in rat knee tissue. Oral 
administration of rebamipide reduced oxidative stress in the 
subchondral bone area and in articular cartilage. Further-
more, the chondroprotective capacity of rebamipide was as-
sociated with reduced catabolism of the articular cartilage 
matrix. ADAMTS5, MMPs, and HIF-2 have also been re-
ported to mediate the ability of rebamipide to serve as an 
anticatabolic regulator of cartilage destruction [15].   
 In the present study, excessive chondrocyte apoptosis and 
enhanced expression of MMP-13 by chondrocytes character-
ized the model of TMJ-OA that was established. Then, fol-
lowing treatment with rebamipide, a dose-dependent attenua-
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tion of cartilage degradation was observed in the hypertro-
phic layer of the condylar cartilage [14]. 
 During the cartilage degradation process, reactive oxygen 
species (ROS) and antioxidants may simultaneously act at 
different levels. Both induction of matrix degradation by 
enzymes and inhibition of matrix formation are involved in 
this process. Based on the role of ROS in mediating an in-
crease in the apoptosis of chondrocytes during OA, ROS 
have been identified as a potential treatment target. In addi-
tion, inhibitor of nitrite oxide, a marker of oxidative stress, 
has been found to be markedly attenuated in TMJ-OA mice 
treated with rebamipide. Thus, the chondroprotective effects 
of rebamipide on cartilage affected by TMJ-OA may be me-
diated by its ROS-scavenging property [14, 77, 81, 82]  
(Fig. 2).  
9. OCs AND ARTICULAR CHONDROCYTE MAL-
FUNCTION IN TMJ-OA AND POTENTIAL EFFECTS 
OF REBAMIPIDE 
 Articular cartilage and subchondral bone are separated by 
a calcified cartilage zone that undergoes marked changes in 
structural, physical, and functional properties of the OA 
process [83]. OC, a multinucleated cell responsible for bone 
resorption, can penetrate the mineralized matrices of the 
bone and calcified cartilage [84]. 
 The penetration site creates fissures and cracks in the 
overlying cartilage and the vascular supplies a mechanism 
for fluids exchange and soluble mediators between these 
tissues. During the OA mechanism progresses, cracks and 
discontinuities also develop in the subchondral bone that 
leads to the mechanism for exchange. There is an evidence 
of communication between the cartilage and subchondral 
bone directly via the diffusion process that allows soluble 
products exchange to regulate the activities of resident cells 
in the adjacent tissues [83, 85, 86].  
 A recent study reported that -catenin signaling in chon-
drocytes plays an important role in postnatal bone growth 
and bone remodeling through OC formation in mice with 
conditional knockout or activation of chondrocyte-specific 
-catenin [87]. A role of -catenin is also identified in the 
regulation of chondrocyte differentiation and function un-
dergo OA condition [88, 89]. Mice with -catenin deficiency 
in chondrocytes exhibit increased RANKL/OPG ratios that 
promote OC-inducing activity. The RANKL/OPG ratio was 
reversed in the chondrocytes from the mice with the activat-
ing mutation, showing impaired osteoclast-inducing activity 
[87].  
 Coculture studies between chondrocyte cells and OC 
precursor cells with M-CSF and 1,25-dihydroxyvitamin D3 
exhibited that the ability of the chondrocytes to support os-
teoclastogenesis could be attributed to their differential ca-
pacity to express RANKL and OPG. OPG acts as a key in-
hibitor of OC differentiation via interaction with RANKL, 
by antagonizing the function of RANKL [90, 91]. However, 
in addition to osteocytes and other OB lineage cells that 
promote RANKL and OPG expression, chondrocytes may 
serve as a potential regulator in osteoclastogenesis. Thus, 
further studies are needed to understand the potential role of 
chondrocytes-derived RANKL/OPG in the pathogenesis of 
OA [91].  
 This present study demonstrated that in murine TMJ-OA, 
rebamipide effectively attenuates the subchondral trabecular 
bone resorption by decreasing number of TRAP-positive 
cells. In OC differentiation process, rebamipide inhibits 
NFATc1 [14], a transcription factor that most potently in-
duced by RANKL [49], followed by lower levels of OC 
function markers such as, integrin 3, c-Src, and cathepsin K 
as well as disrupted actin ring formations (Fig. 1). Rebamip-
ide was also found to significantly inhibit the phosphoryla-
tion of IB, JNK, ERK, and p38 [14]. Therefore, rebamip-
ide has potential effects to overcome osteoclastogenesis mal-
function in murine TMJ-OA (Fig. 2). 
 Cellular interaction in crosstalk in vitro between chon-
drocytes and OBs has been investigated. OBs and articular 
chondrocytes derived from OA bone exhibit decreased pro-
duction of aggrecan and chondrocyte markers (SOX9 and 
type 2 collagen), but increased the production of MMP-3 and 
MMP-13. This finding suggests that local factors expressed 
by OB initiate chondrocyte hypertrophy and matrix miner-
alization [92-94]. In murine TMJ-OA, increased expression 
of MMP-13 and excessive chondrocyte apoptosis was at-
tenuated by treatment with rebamipide. However, in in vitro 
study, rebamipide was neither affected OB mineralization 
nor differentiation [14]. Thus, following investigations of 
rebamipide are needed to provide an effective treatment for 
TMJ-OA patients.  
CONCLUSION 
 In the hypertrophic layer of condylar cartilage, rebamip-
ide-treated TMJ-OA joints underwent marked degradation of 
cartilage, excessive chondrocyte apoptosis, and increased 
expression of MMP-13 by chondrocytes in a dose-dependent 
manner compared to vehicle-treated TMJ-OA joints. To fur-
ther elucidate how these changes affect the homeostasis of 
cartilage ECM and induce chondroprotection, and to deter-
mine whether rebamipide affects the survival of OA chon-
drocytes, additional studies are needed.  
 Differentiation and OC activity in the rebamipide-treated 
TMJ-OA joints were suppressed, while highly effective anti-
resorptive activity was observed, as a result of inhibited tran-
scription factor activity in response to RANKL. Thus, the 
present results support further study of the potential for re-
bamipide to serve as a treatment for TMJ-OA. 
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